Lentigen to manufacture vector for Oncternal

By The Science Advisory Board staff writers

January 14, 2021 -- Oncternal Therapeutics announced an agreement with Lentigen Technology, a subsidiary of Miltenyi Biotec, to manufacture lentiviral vectors for Octernal's investigational receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeting chimeric antigen receptor (CAR) T-cell therapy program.

Lentigen focuses on the design, construction, and production of lentiviral vectors from research through good manufacturing practice (GMP) manufacturing.

Under the agreement, Lentigen will reserve capacity in 2021 to manufacture, test, and release GMP lentivirus vectors to support and accelerate the development of Oncternal's CAR T-cell therapy program.

No financial details of the agreement were disclosed.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?